[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
We report a case of sustained remission of a liver transplant patient infected with hepatitis C virus (HCV) genotype 1 undergoing hemodialysis treatment. Oral treatment regimen of the HCV infection consists of a combination of sofosbuvir 400 mg after each hemodialysis session and daclatasvir 60 mg daily, for a period of 3 months. Laboratory testing indicate that the combination regimen was well-tolerated with no sign of drug-drug interaction. Confirmation of these clinical observations in large clinical studies may help improve morbidity and decrease mortality outcome in patients infected with HCV and undergoing hemodialysis treatment.
Association pour le traitement de l'insuffisance rénale chronique, 350, chemin de Baigne-Pieds, 84000 Avignon, France. Electronic address: mourad.hachicha@atir-avignon.com.
Mourad
M
Hachicha
Service d'hépatologie et de gastroentérologie, CHU La Timone, 264, rue Saint-Pierre, 13005 Marseille, France.
Danielle
D
Botta-Fridlund
D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000601:surgery; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000150:complications / Q000209:etiology / Q000601:surgery / Q000821:virology; D008113:Liver Neoplasms / Q000150:complications / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000628:therapy; D012307:Risk Factors; D000069474:Sofosbuvir / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives
D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir
Antiviraux d’action directe; Daclatasvir; Direct-acting antivirals; Hemodialysis; Hepatitis C; Hémodialyse; Hépatite C; Liver transplantation; Sofosbuvir; Transplantation hépatique